Canadian Cancer Trials Group Bulletins


Canadian Cancer Trials Group Appoints New Director of Translational Research

It is with great pleasure that we inform you that, through a collaborative process with the Ontario Institute for Cancer Research (OICR), Dr. Janet Dancey will join the Canadian Cancer Trials Group in the position of Director, Translational Research -- Clinical, and will be based with us at Queen's University. This appointment will become effective in late September / early October 2008. We are thrilled and privileged to have Dr. Dancey join us.

The enhancement of translational research is a prime strategic direction of the Canadian Cancer Trials Group. In order for continued growth in our capabilities in translational research and biomarker development, we have seen the need to recruit an individual with special expertise to, from a clinical perspective, facilitate our directions and to be a resource for our Correlative Sciences/Tumour Biology and Disease Site Committees. This recruitment will complement our existing strengths provided by Dr. Jeremy Squire, who has recently been recruited to a position of Director, Translational Research Laboratory and Dr. Lois Shepherd, Director of our Tumour/Tissue Data Repository.

Dr. Dancey is an outstanding individual. She received her M.D. from the University of Ottawa in 1988 and completed her residency training in internal medicine and medical oncology at the University of Toronto. In 1994-95, she was a research fellow with the Canadian Cancer Trials Group and followed this in 1995 with additional fellowship training at the Institut Gustave Roussy in France. Her initial faculty appointment was with the University of Toronto from 1997-1999, and, in 1999, she joined the Cancer Therapy Evaluation Program at the US National Cancer Institute as a Senior Clinical Investigator in the Investigational New Drug Branch. In 2007, she was appointed Associate Chief of the Investigational Drug Branch. Dr. Dancey has special expertise in new anti-cancer drug development, linking drug and biomarker development, and associated clinical trials methodology.

The ability to have Dr. Dancey join us has been made possible through special collaboration and support from the Ontario Institute for Cancer Research. In facilitating its strategic direction, OICR has appointed Dr. Dancey as its Director of the High Content Clinical Trials Program. The OICR appointment permits 50% of Dr. Dancey's time to be allocated to her own personal research, which she will direct to her Canadian Cancer Trials Group position. We are very appreciative of our collaboration with OICR and are grateful for their support. We look forward to Dr. Dancey's expertize in forwarding our broad agenda to lead clinical trials that are national/international in scope and result in better outcomes for cancer patients.